China's Kintor says Phase III COVID-19 treatment trial misses statistical criteria

Kintor Pharmaceutical

27/12/2021 11:54

BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical
Ltd  9939.HK  said data from a Phase III clinical trial for its
potential COVID-19 treatment proxalutamide in non-hospitalised
patients did not meet statistical criteria in the interim
analysis.
    Kintor said in a filing on Monday that it will seek
authorities' consent to amend clinical protocol and continue to
enroll patients of higher risk.

 (Reporting by Beijing newsroom; Editing by Kirsten Donovan)
 ((meg.shen@thomsonreuters.com; 852-39525805;))